BPC — Precision Peptide Balance Sheet
0.000.00%
- CA$16.46m
- CA$15.50m
- CA$0.05m
Annual balance sheet for Precision Peptide, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2021 October 31st | R2022 October 31st | 2023 October 31st | 2024 October 31st | 2025 October 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.808 | 0.076 | 0.052 | 0.14 | 0.96 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.084 | 0.131 | 0.048 | 0.024 | 0.071 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 1.28 | 0.472 | 0.176 | 0.182 | 1.33 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.023 | 0.022 | 0.015 | 0 | — |
| Net Intangible Assets | |||||
| Total Assets | 1.34 | 0.503 | 0.192 | 0.182 | 1.33 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.117 | 0.284 | 0.33 | 0.733 | 0.401 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.117 | 0.284 | 0.33 | 0.733 | 0.401 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 1.23 | 0.219 | -0.138 | -0.55 | 0.93 |
| Total Liabilities & Shareholders' Equity | 1.34 | 0.503 | 0.192 | 0.182 | 1.33 |
| Total Common Shares Outstanding |